Inmune Bio (INMB) Price & Analysis

Compare

873 Followers

INMB Stock Chart & Stats

$1.53

-$0.22(-3.95%)

At close: Jan 08 4:00 PM EST

$1.53

-$0.22(-3.95%)

Day’s Range― - ―

52-Week Range$1.38 - $11.64

Previous CloseN/A

Volume114.20K

Average Volume (3M)419.64K

Market Cap

$42.27M

Enterprise Value$15.62M

Total Cash (Recent Filing)$27.73M

Total Debt (Recent Filing)$1.08M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Feb 26, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding26,585,258

10 Day Avg. Volume310,453

30 Day Avg. Volume419,644

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)2.90

Price to Sales (P/S)6652.75

P/FCF Ratio-2.79

Enterprise Value/Market Cap0.37

Enterprise Value/Revenue312.33

Enterprise Value/Gross Profit709.84

Enterprise Value/Ebitda-0.46

Forecast

1Y Price Target

$8.00

Price Target Upside422.88% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy Signal (XPro)A meaningful improvement on a standard Alzheimer's cognitive score in biomarker-defined patients, with an effect size that appears larger than some approved therapies, strengthens the clinical case for XPro and may attract partner interest.

Manufacturing And Scale-upCompletion of two commercial pilot-scale manufacturing runs of CORDSTROM at a United Kingdom facility de-risks scale-up, supports regulatory filings and improves readiness for potential commercialization.

Regulatory ProgressA progressing regulatory filing pathway for CORDSTROM toward marketing authorization in the United Kingdom and subsequent approval in the United States provides a clear regulatory catalyst for the stock.

Bears Say

Competitive Landscape (prostate Cancer)The later-line prostate cancer market is crowded and dominated by effective treatments, making it difficult for INKmune to find a clear commercial niche and limiting upside.

Funding And Class Risk (anti-inflammatory Alzheimer's Approaches)Limited financial resources that constrained the MINDFul trial, together with repeated failures of anti-inflammatory approaches in Alzheimer's disease, heighten execution and scientific risk for related programs.

Trial Setback (Alzheimer's)A phase two Alzheimer's trial missed its primary goals, prompting a pullback in investor sentiment and increasing sensitivity to future study outcomes.

Inmune Bio News

INmune Bio CEO says ‘well positioned for continued execution’

INmune Bio (INMB) presented a letter to investors from David Moss, CEO, which read in part, “As we...

6d ago

INMB

INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Inmune Bio. The associated price target...

5d ago

INMB

INmune Bio outlines 2026 regulatory path in shareholder letter

The latest announcement is out from Inmune Bio ( ($INMB) ). In a shareholder letter dated January 27,...

5d ago

INMB

Inmune Bio Amends April 2024 Investor Warrants

An update from Inmune Bio ( ($INMB) ) is now available. On December 22, 2025, INmune Bio Inc....

1M ago

INMB

INmune Bio Establishes $65 Million At-The-Market Offering

The latest update is out from Inmune Bio ( ($INMB) ). On December 19, 2025, INmune Bio Inc....

1M ago

INMB

Inmune Bio Ends Sales Agreement with RBC and BTIG

Inmune Bio ( ($INMB) ) just unveiled an update. INmune Bio Inc. announced the termination of its Amended...

2M ago

INMB

Inmune Bio Unveils Promising Alzheimer’s Trial Data

Inmune Bio ( ($INMB) ) just unveiled an announcement. On December 1, 2025, INmune Bio Inc. announced new...

2M ago

INMB

INmune Bio publishes study on INmune’s CORDStrom platform

INmune Bio (INMB) announces a recently published overview of future applications and research areas for mesenchymal stromal cell...

2M ago

INMB

Inmune Bio Updates Executive Employment Agreements

Inmune Bio ( ($INMB) ) has issued an update. On December 2, 2025, INmune Bio Inc. announced amendments...

2M ago

INMB

INmune Bio announces neuroimaging data from Phase 2 MINDFuL trial

INmune Bio (INMB) announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with...

2M ago

INMB

Inmune Bio Announces New Executive Employment Agreements

Inmune Bio ( ($INMB) ) has issued an update. On November 26, 2025, INmune Bio Inc. announced new...

2M ago

INMB

INmune Bio Approves Option Repricing Proposal

Inmune Bio ( ($INMB) ) has issued an update. On November 18, 2025, INmune Bio held a virtual...

3M ago

INMB

Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion

Inmune Bio ( ($INMB) ) has provided an update. INmune Bio Inc. has prepared a presentation slide deck...

3M ago

INMB

INmune Bio reports Q3 EPS (24c), consensus (32c)

As of September 30, the company had cash and cash equivalents of approximately $27.7M. Published first on TheFly...

3M ago

INMB

INMB FAQ

What was Inmune Bio Inc’s price range in the past 12 months?

Inmune Bio Inc lowest stock price was $1.38 and its highest was $11.64 in the past 12 months.

What is Inmune Bio Inc’s market cap?

Inmune Bio Inc’s market cap is $42.27M.

When is Inmune Bio Inc’s upcoming earnings report date?

Inmune Bio Inc’s upcoming earnings report date is Feb 26, 2026 which is in 24 days.

How were Inmune Bio Inc’s earnings last quarter?

Inmune Bio Inc released its earnings results on Oct 30, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.

Is Inmune Bio Inc overvalued?

According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inmune Bio Inc pay dividends?

Inmune Bio Inc does not currently pay dividends.

What is Inmune Bio Inc’s EPS estimate?

Inmune Bio Inc’s EPS estimate is -0.24.

How many shares outstanding does Inmune Bio Inc have?

Inmune Bio Inc has 26,585,258 shares outstanding.

What happened to Inmune Bio Inc’s price movement after its last earnings report?

Inmune Bio Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 5.78%.

Which hedge fund is a major shareholder of Inmune Bio Inc?

Currently, no hedge funds are holding shares in INMB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inmune Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-155.77%

Trailing 12-Months

Asset Growth

-36.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Inmune Bio (INMB) Earnings & Revenues

Historic Earnings Reports

INMB Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.View all INMB earnings summaries

INMB Stock 12 Month Forecast

Average Price Target

$8.00

▲(422.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,2.0553846153846154,2.5507692307692307,3.046153846153846,3.5415384615384617,4.0369230769230775,4.532307692307692,5.027692307692307,5.523076923076923,6.018461538461539,6.5138461538461545,7.0092307692307685,7.504615384615384,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,2.0553846153846154,2.5507692307692307,3.046153846153846,3.5415384615384617,4.0369230769230775,4.532307692307692,5.027692307692307,5.523076923076923,6.018461538461539,6.5138461538461545,7.0092307692307685,7.504615384615384,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,2.0553846153846154,2.5507692307692307,3.046153846153846,3.5415384615384617,4.0369230769230775,4.532307692307692,5.027692307692307,5.523076923076923,6.018461538461539,6.5138461538461545,7.0092307692307685,7.504615384615384,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >